Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173

1.

Increased platelet activation in sleep apnea subjects with intermittent hypoxemia.

Krieger AC, Anand R, Hernandez-Rosa E, Maidman A, Milrad S, DeGrazia MQ, Choi AJ, Oromendia C, Marcus AJ, Drosopoulos JHF.

Sleep Breath. 2020 Feb 8. doi: 10.1007/s11325-020-02021-4. [Epub ahead of print]

PMID:
32036486
2.

Intraocular pressure-lowering effects of imidazo[1,2-a]- and pyrimido[1,2-a]benzimidazole compounds in rats with dexamethasone-induced ocular hypertension.

Marcus AJ, Iezhitsa I, Agarwal R, Vassiliev P, Spasov A, Zhukovskaya O, Anisimova V, Ismail NM.

Eur J Pharmacol. 2019 May 5;850:75-87. doi: 10.1016/j.ejphar.2019.01.059. Epub 2019 Feb 1.

PMID:
30716317
3.

Data on the effects of imidazo[1,2-a]benzimidazole and pyrimido[1,2-a]benzimidazole compounds on intraocular pressure of ocular normotensive rats.

Marcus AJ, Iezhitsa I, Agarwal R, Vassiliev P, Spasov A, Zhukovskaya O, Anisimova V, Mohd Ismail N.

Data Brief. 2018 Mar 8;18:523-554. doi: 10.1016/j.dib.2018.03.019. eCollection 2018 Jun.

4.

Relationship between intraocular pressure lowering effect and chemical structure of imidazo[1,2-a]benzimidazole and pyrimido[1,2-a]benzimidazole derivatives.

Vassiliev P, Iezhitsa I, Agarwal R, Marcus AJ, Spasov A, Zhukovskaya O, Anisimova V.

Data Brief. 2018 Mar 6;18:340-347. doi: 10.1016/j.dib.2018.02.067. eCollection 2018 Jun.

5.

Intraocular pressure lowering effect and structure-activity relationship of imidazo[1,2-a]benzimidazole and pyrimido[1,2-a]benzimidazole compounds in ocular normotensive rats: Insight on possible link with hypotensive activity.

Marcus AJ, Iezhitsa I, Agarwal R, Vassiliev P, Spasov A, Zhukovskaya O, Anisimova V, Johari B, Mohd Ismail N.

Eur J Pharm Sci. 2018 Mar 1;114:245-254. doi: 10.1016/j.ejps.2017.12.015. Epub 2017 Dec 21.

PMID:
29274441
6.

E-NTPDase1/CD39 modulates renin release from heart mast cells during ischemia/reperfusion: a novel cardioprotective role.

Aldi S, Marino A, Tomita K, Corti F, Anand R, Olson KE, Marcus AJ, Levi R.

FASEB J. 2015 Jan;29(1):61-9. doi: 10.1096/fj.14-261867. Epub 2014 Oct 15.

7.

Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk.

Moeckel D, Jeong SS, Sun X, Broekman MJ, Nguyen A, Drosopoulos JH, Marcus AJ, Robson SC, Chen R, Abendschein D.

Sci Transl Med. 2014 Aug 6;6(248):248ra105. doi: 10.1126/scitranslmed.3009246.

8.

New approaches for measurement of platelet reactivity.

Marcus AJ.

Blood. 2012 Apr 12;119(15):3378-9. doi: 10.1182/blood-2012-01-403717.

PMID:
22500052
9.

CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia.

Pulte D, Furman RR, Broekman MJ, Drosopoulos JH, Ballard HS, Olson KE, Kizer JR, Marcus AJ.

Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):367-72. doi: 10.1016/j.clml.2011.06.005.

10.

The expression level of ecto-NTP diphosphohydrolase1/CD39 modulates exocytotic and ischemic release of neurotransmitters in a cellular model of sympathetic neurons.

Corti F, Olson KE, Marcus AJ, Levi R.

J Pharmacol Exp Ther. 2011 May;337(2):524-32. doi: 10.1124/jpet.111.179994. Epub 2011 Feb 16.

11.

Feedback regulation of endothelial cell surface plasmin generation by PKC-dependent phosphorylation of annexin A2.

He KL, Sui G, Xiong H, Broekman MJ, Huang B, Marcus AJ, Hajjar KA.

J Biol Chem. 2011 Apr 29;286(17):15428-39. doi: 10.1074/jbc.M110.185058. Epub 2010 Nov 29.

12.

Human solCD39 inhibits injury-induced development of neointimal hyperplasia.

Drosopoulos JH, Kraemer R, Shen H, Upmacis RK, Marcus AJ, Musi E.

Thromb Haemost. 2010 Feb;103(2):426-34. doi: 10.1160/TH09-05-0305. Epub 2009 Dec 18.

13.

Homocysteine inhibits neoangiogenesis in mice through blockade of annexin A2-dependent fibrinolysis.

Jacovina AT, Deora AB, Ling Q, Broekman MJ, Almeida D, Greenberg CB, Marcus AJ, Smith JD, Hajjar KA.

J Clin Invest. 2009 Nov;119(11):3384-94. doi: 10.1172/JCI39591. Epub 2009 Oct 19.

14.

P2X(1) receptor inhibition and soluble CD39 administration as novel approaches to widen the cardiovascular therapeutic window.

Fung CY, Marcus AJ, Broekman MJ, Mahaut-Smith MP.

Trends Cardiovasc Med. 2009 Jan;19(1):1-5. doi: 10.1016/j.tcm.2009.01.005. Review.

15.

Self-regulation of inflammatory cell trafficking in mice by the leukocyte surface apyrase CD39.

Hyman MC, Petrovic-Djergovic D, Visovatti SH, Liao H, Yanamadala S, Bouïs D, Su EJ, Lawrence DA, Broekman MJ, Marcus AJ, Pinsky DJ.

J Clin Invest. 2009 May;119(5):1136-49. doi: 10.1172/JCI36433. Epub 2009 Apr 20.

16.

Fate of amnion-derived stem cells transplanted to the fetal rat brain: migration, survival and differentiation.

Marcus AJ, Coyne TM, Black IB, Woodbury D.

J Cell Mol Med. 2008 Aug;12(4):1256-64. doi: 10.1111/j.1582-4934.2008.00180.x.

17.

Fetal stem cells from extra-embryonic tissues: do not discard.

Marcus AJ, Woodbury D.

J Cell Mol Med. 2008 Jun;12(3):730-42. doi: 10.1111/j.1582-4934.2008.00221.x. Epub 2008 Jan 11. Review.

18.

Disparate host response and donor survival after the transplantation of mesenchymal or neuroectodermal cells to the intact rodent brain.

Coyne TM, Marcus AJ, Reynolds K, Black IB, Woodbury D.

Transplantation. 2007 Dec 15;84(11):1507-16.

PMID:
18091528
19.

Isolation, characterization, and differentiation of stem cells derived from the rat amniotic membrane.

Marcus AJ, Coyne TM, Rauch J, Woodbury D, Black IB.

Differentiation. 2008 Feb;76(2):130-44. Epub 2007 Jul 2.

PMID:
17608732
20.

Targeted deletion of ectonucleoside triphosphate diphosphohydrolase 1/CD39 leads to desensitization of pre- and postsynaptic purinergic P2 receptors.

Schaefer U, Machida T, Broekman MJ, Marcus AJ, Levi R.

J Pharmacol Exp Ther. 2007 Sep;322(3):1269-77. Epub 2007 Jun 12.

PMID:
17565006
21.

CD39/NTPDase-1 activity and expression in normal leukocytes.

Pulte ED, Broekman MJ, Olson KE, Drosopoulos JH, Kizer JR, Islam N, Marcus AJ.

Thromb Res. 2007;121(3):309-17. Epub 2007 Jun 7.

22.

CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia.

Pulte D, Olson KE, Broekman MJ, Islam N, Ballard HS, Furman RR, Olson AE, Marcus AJ.

J Transl Med. 2007 May 4;5:23.

23.

Access to the superficial femoral artery in the presence of a "hostile groin": a prospective study.

Marcus AJ, Lotzof K, Howard A.

Cardiovasc Intervent Radiol. 2007 May-Jun;30(3):351-4.

PMID:
17295080
24.

Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization.

Kopp HG, Hooper AT, Broekman MJ, Avecilla ST, Petit I, Luo M, Milde T, Ramos CA, Zhang F, Kopp T, Bornstein P, Jin DK, Marcus AJ, Rafii S.

J Clin Invest. 2006 Dec;116(12):3277-91.

25.

Long-term cryopreserved amniocytes retain proliferative capacity and differentiate to ectodermal and mesodermal derivatives in vitro.

Woodbury D, Kramer BC, Reynolds K, Marcus AJ, Coyne TM, Black IB.

Mol Reprod Dev. 2006 Nov;73(11):1463-72.

PMID:
16894552
26.
27.

Aspirin therapy for inhibition of platelet reactivity in the presence of erythrocytes in patients with vascular disease.

Santos MT, Vallés J, Aznar J, Lago A, Sanchez E, Cosin J, Moscardó A, Piñón M, Broekman MJ, Marcus AJ.

J Lab Clin Med. 2006 May;147(5):220-7.

28.

A new approach: regional nerve blockade for angioplasty of the lower limb.

Marcus AJ, Lotzof K, Kamath BS, Shanthakumar RE, Munir N, Loh A, Bird R, Howard A.

Cardiovasc Intervent Radiol. 2006 Mar-Apr;29(2):235-40.

PMID:
16391953
29.

Effects of SolCD39, a novel inhibitor of Platelet Aggregation, on Platelet Deposition and Aggregation after PTCA in a Porcine Model.

Buergler JM, Maliszewski CR, Broekman MJ, Kaluza GL, Schulz DG, Marcus AJ, Raizner AE, Kleiman NS, Ali NM.

J Thromb Thrombolysis. 2005 Apr;19(2):115-22.

PMID:
16052302
30.

The ratio of ADP- to ATP-ectonucleotidase activity is reduced in patients with coronary artery disease.

El-Omar MM, Islam N, Broekman MJ, Drosopoulos JH, Roa DC, Lorin JD, Sedlis SP, Olson KE, Pulte ED, Marcus AJ.

Thromb Res. 2005;116(3):199-206. Epub 2004 Dec 21.

PMID:
15935828
31.

Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection.

Marcus AJ, Broekman MJ, Drosopoulos JH, Olson KE, Islam N, Pinsky DJ, Levi R.

Semin Thromb Hemost. 2005 Apr;31(2):234-46. Review.

PMID:
15852226
32.

Ectonucleoside triphosphate diphosphohydrolase 1/CD39, localized in neurons of human and porcine heart, modulates ATP-induced norepinephrine exocytosis.

Machida T, Heerdt PM, Reid AC, Schäfer U, Silver RB, Broekman MJ, Marcus AJ, Levi R.

J Pharmacol Exp Ther. 2005 May;313(2):570-7. Epub 2005 Jan 12.

PMID:
15647328
34.

Adult bone marrow stromal cells in the embryonic brain: engraftment, migration, differentiation, and long-term survival.

Muñoz-Elias G, Marcus AJ, Coyne TM, Woodbury D, Black IB.

J Neurosci. 2004 May 12;24(19):4585-95.

35.

Heterologous cell-cell interactions: thromboregulation, cerebroprotection and cardioprotection by CD39 (NTPDase-1).

Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Pinsky DJ, Sesti C, Levi R.

J Thromb Haemost. 2003 Dec;1(12):2497-509. Review. Erratum in: J Thromb Haemost. 2004 Apr;2(4):682.

36.

Ectonucleotidase in sympathetic nerve endings modulates ATP and norepinephrine exocytosis in myocardial ischemia.

Sesti C, Koyama M, Broekman MJ, Marcus AJ, Levi R.

J Pharmacol Exp Ther. 2003 Jul;306(1):238-44. Epub 2003 Apr 3.

PMID:
12676879
37.

Metabolic control of excessive extracellular nucleotide accumulation by CD39/ecto-nucleotidase-1: implications for ischemic vascular diseases.

Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Pinsky DJ, Sesti C, Levi R.

J Pharmacol Exp Ther. 2003 Apr;305(1):9-16. Review.

PMID:
12649347
38.

Cell-type specificity of ectonucleotidase expression and upregulation by 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Wood E, Broekman MJ, Kirley TL, Diani-Moore S, Tickner M, Drosopoulos JH, Islam N, Park JI, Marcus AJ, Rifkind AB.

Arch Biochem Biophys. 2002 Nov 1;407(1):49-62.

PMID:
12392715
39.

COX inhibitors and thromboregulation.

Marcus AJ, Broekman MJ, Pinsky DJ.

N Engl J Med. 2002 Sep 26;347(13):1025-6. Review. No abstract available.

PMID:
12324561
40.

Role of extracellular ATP metabolism in regulation of platelet reactivity.

Birk AV, Broekman MJ, Gladek EM, Robertson HD, Drosopoulos JH, Marcus AJ, Szeto HH.

J Lab Clin Med. 2002 Sep;140(3):166-75.

PMID:
12271274
41.

Platelet-erythrocyte interactions enhance alpha(IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo.

Vallés J, Santos MT, Aznar J, Martínez M, Moscardó A, Piñón M, Broekman MJ, Marcus AJ.

Blood. 2002 Jun 1;99(11):3978-84.

PMID:
12010797
42.

Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain.

Pinsky DJ, Broekman MJ, Peschon JJ, Stocking KL, Fujita T, Ramasamy R, Connolly ES Jr, Huang J, Kiss S, Zhang Y, Choudhri TF, McTaggart RA, Liao H, Drosopoulos JH, Price VL, Marcus AJ, Maliszewski CR.

J Clin Invest. 2002 Apr;109(8):1031-40.

43.

Role of a novel soluble nucleotide phospho-hydrolase from sheep plasma in inhibition of platelet reactivity: hemostasis, thrombosis, and vascular biology.

Birk AV, Bubman D, Broekman MJ, Robertson HD, Drosopoulos JH, Marcus AJ, Szeto HH.

J Lab Clin Med. 2002 Feb;139(2):116-24.

PMID:
11919550
44.

EctoNucleotidase in cardiac sympathetic nerve endings modulates ATP-mediated feedback of norepinephrine release.

Sesti C, Broekman MJ, Drosopoulos JH, Islam N, Marcus AJ, Levi R.

J Pharmacol Exp Ther. 2002 Feb;300(2):605-11.

PMID:
11805223
45.

Inhibition of platelet recruitment by endothelial cell CD39/ecto-ADPase: significance for occlusive vascular diseases.

Marcus AJ, Broekman MJ, Drosopoulos JH, Pinsky DJ, Islam N, Maliszewsk CR.

Ital Heart J. 2001 Nov;2(11):824-30.

PMID:
11770867
46.

Participation of tyrosine phosphorylation in cytoskeletal reorganization, alpha(IIb)beta(3) integrin receptor activation, and aspirin-insensitive mechanisms of thrombin-stimulated human platelets.

Santos MT, Moscardó A, Vallés J, Martínez M, Piñón M, Aznar J, Broekman MJ, Marcus AJ.

Circulation. 2000 Oct 17;102(16):1924-30.

PMID:
11034940
47.

Site-directed mutagenesis of human endothelial cell ecto-ADPase/soluble CD39: requirement of glutamate 174 and serine 218 for enzyme activity and inhibition of platelet recruitment.

Drosopoulos JH, Broekman MJ, Islam N, Maliszewski CR, Gayle RB 3rd, Marcus AJ.

Biochemistry. 2000 Jun 13;39(23):6936-43.

PMID:
10841775
48.

Aspirin analogs as antithrombotic agents.

Marcus AJ, Broekman MJ.

J Lab Clin Med. 1998 Dec;132(6):446-7. Review. No abstract available.

PMID:
9851731
49.
50.

Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39.

Gayle RB 3rd, Maliszewski CR, Gimpel SD, Schoenborn MA, Caspary RG, Richards C, Brasel K, Price V, Drosopoulos JH, Islam N, Alyonycheva TN, Broekman MJ, Marcus AJ.

J Clin Invest. 1998 May 1;101(9):1851-9.

Supplemental Content

Loading ...
Support Center